Overcoming the impact of the COVID‐19 pandemic on oncology early phase trials and drug development in Asia—Experiences and perspectives of the Asian Oncology Early Phase 1 Consortium

AIM: The significance and prioritization of early phase oncology trial continuation during a global pandemic is unknown. This study reported the outcomes, multiple challenges, and broad recommendations associated with the impact of the novel coronavirus disease 2019 (COVID‐19) on oncology early phas...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Asia Pac J Clin Oncol
Autors principals: Shimizu, Toshio, Kim, Dong‐Wan, Loong, Herbert H., Lin, Chia‐Chi, Ng, Matthew CH, Yamamoto, Noboru, Ma, Brigette, Tan, Daniel SW
Format: Artigo
Idioma:Inglês
Publicat: John Wiley and Sons Inc. 2021
Matèries:
Original Articles
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC8014030/
https://ncbi.nlm.nih.gov/pubmed/33502085
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/ajco.13510
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars